{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:31:09Z","timestamp":1793997069392,"version":"4.8.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8134","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,10,1]]},"DOI":"10.1038\/s41586-026-10998-3","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:02:09Z","timestamp":1788966129000},"page":"241-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["TRI-611, a selective, brain-penetrant molecular glue degrader of ALK"],"prefix":"10.1038","volume":"658","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3638-7633","authenticated-orcid":false,"given":"Andrew R.","family":"Conery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artyom A.","family":"Alekseyenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Marcoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron G.","family":"Bart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt L.","family":"Harlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R.","family":"Arsenault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9709-8830","authenticated-orcid":false,"given":"Nico R.","family":"Cantone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Casaubon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Constan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari B.","family":"Kamadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aravind Prasad","family":"Medikonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3652-0282","authenticated-orcid":false,"given":"Duncan E.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Szeto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim J.","family":"Wigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Zagulyaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Highfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6127-318X","authenticated-orcid":false,"given":"Aaron N.","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5511-2825","authenticated-orcid":false,"given":"Kenneth","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jisu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1974-5921","authenticated-orcid":false,"given":"Prafulla C.","family":"Gokhale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Germa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen I.","family":"Seyb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Trojer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2939-7053","authenticated-orcid":false,"given":"Vito J.","family":"Palombella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"10998_CR1","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","volume":"4","author":"JL Schneider","year":"2023","unstructured":"Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat Cancer 4, 330\u2013343 (2023).","journal-title":"Nat Cancer"},{"key":"10998_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","volume":"25","author":"C Voena","year":"2025","unstructured":"Voena, C., Ambrogio, C., Iannelli, F. & Chiarle, R. ALK in cancer: from function to therapeutic targeting. Nat. Rev. Cancer 25, 359\u2013378 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"10998_CR3","doi-asserted-by":"publisher","unstructured":"Shaw, A. T. et al. Lorlatinib versus crizotinib as first-line treatment for advanced ALK-positive non-small-cell lung cancer: 7-year update from the phase III CROWN study. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2026.05.692 (2026).","DOI":"10.1016\/j.annonc.2026.05.692"},{"key":"10998_CR4","doi-asserted-by":"publisher","unstructured":"Saifudeen, M. et al. Comprehensive profiling of clinically approved kinase inhibitors reveals mutation-specific inhibitors and opportunities for drug repurposing. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-026-03090-8 (2026).","DOI":"10.1038\/s41587-026-03090-8"},{"key":"10998_CR5","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1158\/2159-8290.CD-17-1256","volume":"8","author":"S Yoda","year":"2018","unstructured":"Yoda, S. et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-positive lung cancer. Cancer Discov. 8, 714\u2013729 (2018).","journal-title":"Cancer Discov."},{"key":"10998_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107954","volume":"196","author":"Y Igawa","year":"2024","unstructured":"Igawa, Y. et al. Association between lorlatinib blood concentration and adverse events and clinical impact of dose modification. Lung Cancer 196, 107954 (2024).","journal-title":"Lung Cancer"},{"key":"10998_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101\u2013114 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"10998_CR8","doi-asserted-by":"publisher","first-page":"5524","DOI":"10.1021\/acs.jmedchem.2c01864","volume":"66","author":"Y Gao","year":"2023","unstructured":"Gao, Y. et al. Catalytic degraders effectively address kinase site mutations in EML4-ALK oncogenic fusions. J. Med. Chem. 66, 5524\u20135535 (2023).","journal-title":"J. Med. Chem."},{"key":"10998_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.bbrc.2018.09.169","volume":"505","author":"CH Kang","year":"2018","unstructured":"Kang, C. H. et al. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). Biochem. Biophys. Res. Commun. 505, 542\u2013547 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10998_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109015","volume":"27","author":"X Li","year":"2024","unstructured":"Li, X. et al. A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance. iScience 27, 109015 (2024).","journal-title":"iScience"},{"key":"10998_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113335","volume":"217","author":"C Ren","year":"2021","unstructured":"Ren, C. et al. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from alectinib. Eur. J. Med. Chem. 217, 113335 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"10998_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112190","volume":"193","author":"N Sun","year":"2020","unstructured":"Sun, N. et al. Development of a brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance. Eur. J. Med. Chem. 193, 112190 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"10998_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.113150","volume":"212","author":"G Yan","year":"2021","unstructured":"Yan, G. et al. Discovery of a PROTAC targeting ALK with in vivo activity. Eur. J. Med. Chem. 212, 113150 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"10998_CR14","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ejmech.2018.03.071","volume":"151","author":"C Zhang","year":"2018","unstructured":"Zhang, C. et al. Proteolysis targeting chimeras (PROTACs) of anaplastic lymphoma kinase (ALK). Eur. J. Med. Chem. 151, 304\u2013314 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"10998_CR15","doi-asserted-by":"crossref","unstructured":"La, D. S., Nasveschuk, C. G. & Gilbert, A. M. in 2025 Medicinal Chemistry Reviews Medicinal Chemistry Reviews (eds Rudolph, J. & Watkins, W.) 399\u2013427 (ACS, 2025).","DOI":"10.1021\/mc-2025-vol60.ch16"},{"key":"10998_CR16","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.chembiol.2021.04.009","volume":"28","author":"Z Kozicka","year":"2021","unstructured":"Kozicka, Z. & Thoma, N. H. Haven\u2019t got a glue: protein surface variation for the design of molecular glue degraders. Cell Chem. Biol 28, 1032\u20131047 (2021).","journal-title":"Cell Chem. Biol"},{"key":"10998_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-cancerbio-061824-105806","volume":"9","author":"V Vetma","year":"2025","unstructured":"Vetma, V., O\u2019Connor, S. & Ciulli, A. Development of PROTAC degrader drugs for cancer. Annual Rev. Cancer Biol. 9, 119\u2013140 (2025).","journal-title":"Annual Rev. Cancer Biol."},{"key":"10998_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.jconrel.2024.06.057","volume":"372","author":"P Agarwal","year":"2024","unstructured":"Agarwal, P., Reid, D. L. & Amiji, M. CNS delivery of targeted protein degraders. J. Control. Release 372, 661\u2013673 (2024).","journal-title":"J. Control. Release"},{"key":"10998_CR19","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1021\/acschemneuro.6b00029","volume":"7","author":"TT Wager","year":"2016","unstructured":"Wager, T. T., Hou, X., Verhoest, P. R. & Villalobos, A. Central nervous system multiparameter optimization desirability: application in drug discovery. ACS Chem. Neurosci. 7, 767\u2013775 (2016).","journal-title":"ACS Chem. Neurosci."},{"key":"10998_CR20","unstructured":"La, D. et al. Anaplastic lymphoma kinase (ALK) degraders and uses thereof. US patent WO\/2026\/035999 (2026)."},{"key":"10998_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41571-020-0408-9","volume":"18","author":"A Drilon","year":"2021","unstructured":"Drilon, A. et al. ROS1-dependent cancers\u2014biology, diagnostics and therapeutics. Nat. Rev. Clin. Oncol. 18, 35\u201355 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10998_CR22","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jtho.2020.12.022","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge, D. R. Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC. J. Thorac. Oncol. 16, 528\u2013531 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"10998_CR23","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/j.annonc.2020.05.006","volume":"31","author":"D Liu","year":"2020","unstructured":"Liu, D. et al. Characterization of on-target adverse events caused by TRK inhibitor therapy. Ann. Oncol. 31, 1207\u20131215 (2020).","journal-title":"Ann. Oncol."},{"key":"10998_CR24","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nature18611","volume":"535","author":"ME Matyskiela","year":"2016","unstructured":"Matyskiela, M. E. et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252\u2013257 (2016).","journal-title":"Nature"},{"key":"10998_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44698-1","volume":"15","author":"G Nishiguchi","year":"2024","unstructured":"Nishiguchi, G. et al. Selective CK1\u03b1 degraders exert antiproliferative activity against a broad range of human cancer cell lines. Nat. Commun. 15, 482 (2024).","journal-title":"Nat. Commun."},{"key":"10998_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","volume":"19","author":"H Sakamoto","year":"2011","unstructured":"Sakamoto, H. et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19, 679\u2013690 (2011).","journal-title":"Cancer Cell"},{"key":"10998_CR27","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"ER Watson","year":"2022","unstructured":"Watson, E. R. et al. Molecular glue CELMoD compounds are regulators of cereblon conformation. Science 378, 549\u2013553 (2022).","journal-title":"Science"},{"key":"10998_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nature16979","volume":"532","author":"G Petzold","year":"2016","unstructured":"Petzold, G., Fischer, E. S. & Thoma, N. H. Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4(CRBN) ubiquitin ligase. Nature 532, 127\u2013130 (2016).","journal-title":"Nature"},{"key":"10998_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/science.adt6736","volume":"389","author":"G Petzold","year":"2025","unstructured":"Petzold, G. et al. Mining the CRBN target space redefines rules for molecular glue-induced neosubstrate recognition. Science 389, eadt6736 (2025).","journal-title":"Science"},{"key":"10998_CR30","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","volume":"372","author":"E Krissinel","year":"2007","unstructured":"Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774\u2013797 (2007).","journal-title":"J. Mol. Biol."},{"key":"10998_CR31","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","volume":"3","author":"A Shiba-Ishii","year":"2022","unstructured":"Shiba-Ishii, A. et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat. Cancer 3, 710\u2013722 (2022).","journal-title":"Nat. Cancer"},{"key":"10998_CR32","unstructured":"Highlights of Prescribing Information for Lorbrena https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/210868s004lbl.pdf (2021)."},{"key":"10998_CR33","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","volume":"28","author":"HY Zou","year":"2015","unstructured":"Zou, H. Y. et al. PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 28, 70\u201381 (2015).","journal-title":"Cancer Cell"},{"key":"10998_CR34","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nbt.2620","volume":"31","author":"M Taipale","year":"2013","unstructured":"Taipale, M. et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat. Biotechnol. 31, 630\u2013637 (2013).","journal-title":"Nat. Biotechnol."},{"key":"10998_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","volume":"14","author":"JM Pacheco","year":"2019","unstructured":"Pacheco, J. M. et al. Natural history and factors associated with overall survival in stage IV ALK-rearranged non-small cell lung cancer. J. Thorac. Oncol. 14, 691\u2013700 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"10998_CR36","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1158\/2159-8290.CD-24-0231","volume":"14","author":"JJ Lin","year":"2024","unstructured":"Lin, J. J. et al. NVL-655 is a selective and brain-penetrant inhibitor of diverse ALK-mutant oncoproteins, including lorlatinib-resistant compound mutations. Cancer Discov. 14, 2367\u20132386 (2024).","journal-title":"Cancer Discov."},{"key":"10998_CR37","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/s41586-024-07224-3","volume":"628","author":"J Poirson","year":"2024","unstructured":"Poirson, J. et al. Proteome-scale discovery of protein degradation and stabilization effectors. Nature 628, 878\u2013886 (2024).","journal-title":"Nature"},{"key":"10998_CR38","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.molcel.2019.12.013","volume":"77","author":"KM Reichermeier","year":"2020","unstructured":"Reichermeier, K. M. et al. PIKES analysis reveals response to degraders and key regulatory mechanisms of the CRL4 network. Mol. Cell 77, 1092\u20131106 e1099 (2020).","journal-title":"Mol. Cell"},{"key":"10998_CR39","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1016\/j.cell.2020.04.034","volume":"181","author":"M Orthofer","year":"2020","unstructured":"Orthofer, M. et al. Identification of ALK in thinness. Cell 181, 1246\u20131262 (2020).","journal-title":"Cell"},{"key":"10998_CR40","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/s41589-018-0129-x","volume":"14","author":"ME Matyskiela","year":"2018","unstructured":"Matyskiela, M. E. et al. SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate. Nat. Chem. Biol. 14, 981\u2013987 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"10998_CR41","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/JCO.2026.44.16_suppl.8503","volume":"44","author":"JJ Lin","year":"2026","unstructured":"Lin, J. J. et al. ALKOVE-1: efficacy and safety of neladalkib in patients with advanced ALK+ NSCLC. J. Clin. Oncol. 44, 8503\u20138503 (2026).","journal-title":"J. Clin. Oncol."},{"key":"10998_CR42","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","volume":"26","author":"I Dagogo-Jack","year":"2020","unstructured":"Dagogo-Jack, I. et al. MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer. Clin. Cancer Res. 26, 2535\u20132545 (2020).","journal-title":"Clin. Cancer Res."},{"key":"10998_CR43","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1016\/j.ccell.2024.08.004","volume":"42","author":"CA Eide","year":"2024","unstructured":"Eide, C. A. et al. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell 42, 1486\u20131488 (2024).","journal-title":"Cancer Cell"},{"key":"10998_CR44","doi-asserted-by":"publisher","unstructured":"Nagasaka, M. et al. The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib. NPJ Precis. Oncol. https:\/\/doi.org\/10.1038\/s41698-026-01477-z (2026).","DOI":"10.1038\/s41698-026-01477-z"},{"key":"10998_CR45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2023-174177","volume":"142","author":"S Bird","year":"2023","unstructured":"Bird, S. & Pawlyn, C. IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact. Blood 142, 131\u2013140 (2023).","journal-title":"Blood"},{"key":"10998_CR46","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-023-06303-1","volume":"620","author":"H Isozaki","year":"2023","unstructured":"Isozaki, H. et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature 620, 393\u2013401 (2023).","journal-title":"Nature"},{"key":"10998_CR47","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","volume":"20","author":"R Katayama","year":"2014","unstructured":"Katayama, R. et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin. Cancer Res. 20, 5686\u20135696 (2014).","journal-title":"Clin. Cancer Res."},{"key":"10998_CR48","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jsb.2016.04.010","volume":"195","author":"JM de la Rosa-Trevin","year":"2016","unstructured":"de la Rosa-Trevin, J. M. et al. Scipion: A software framework toward integration, reproducibility and validation in 3D electron microscopy. J. Struct. Biol. 195, 93\u201399 (2016).","journal-title":"J. Struct. Biol."},{"key":"10998_CR49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jsb.2012.09.006","volume":"180","author":"SH Scheres","year":"2012","unstructured":"Scheres, S. H. RELION: implementation of a Bayesian approach to cryo-EM structure determination. J. Struct. Biol. 180, 519\u2013530 (2012).","journal-title":"J. Struct. Biol."},{"key":"10998_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/pro.4792","volume":"32","author":"EC Meng","year":"2023","unstructured":"Meng, E. C. et al. UCSF ChimeraX: tools for structure building and analysis. Protein Sci. 32, e4792 (2023).","journal-title":"Protein Sci."},{"key":"10998_CR51","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1107\/S2059798318002425","volume":"74","author":"TI Croll","year":"2018","unstructured":"Croll, T. I. ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps. Acta Crystallogr. D 74, 519\u2013530 (2018).","journal-title":"Acta Crystallogr. D"},{"key":"10998_CR52","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D"},{"key":"10998_CR53","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1107\/S2059798321009475","volume":"77","author":"K Yamashita","year":"2021","unstructured":"Yamashita, K., Palmer, C. M., Burnley, T. & Murshudov, G. N. Cryo-EM single-particle structure refinement and map calculation using Servalcat. Acta Crystallogr. D 77, 1282\u20131291 (2021).","journal-title":"Acta Crystallogr. D"},{"key":"10998_CR54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume":"1263","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 1263, 243\u2013250 (2015).","journal-title":"Methods Mol. Biol."},{"key":"10998_CR55","doi-asserted-by":"publisher","unstructured":"MacLean, B. et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics https:\/\/doi.org\/10.1093\/bioinformatics\/btq054 (2010).","DOI":"10.1093\/bioinformatics\/btq054"},{"key":"10998_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1124\/jpet.114.217141","volume":"351","author":"S Yamazaki","year":"2014","unstructured":"Yamazaki, S. et al. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. J. Pharmacol. Exp. Ther. 351, 67\u201376 (2014).","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10998-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10998-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:29:06Z","timestamp":1790832546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10998-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":56,"journal-issue":{"issue":"8134","published-print":{"date-parts":[[2026,10,1]]}},"alternative-id":["10998"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10998-3","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.R.C., D.S.L., K.I.S., A.A.A., A.G.B., M.L.H., P.R.A., N.R.C., D.E.N., H.S., A.Z., C.M.Z., D.M., P.R.A., T.J.W., H.B.K., A.P.M., R.L.C., A.C., M.Y., C.G., P.T. and V.J.P. are employees of Triana Biomedicines. A.N.H. has received research grants from Amgen, BridgeBio Oncology Therapeutics, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Immuto Scientific, Novartis, Nuvalent, Pfizer, Scorpion Therapeutics and Triana Biomedicines, and consulting fees from Nuvalent. A patent covering TRI-611 has been published as WO2026035999 A1 (Triana Biomedicines) with D.S.L., D.M., A.P.M., A.G.B., M.Y. and R.L.C. listed as inventors.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}